Pancreatic Cancer Update, Issue 1, 2020 (Audio Program)


Interview with Michael J Pishvaian, MD, PhD

Track 1: Key biologic features of pancreatic cancer
Track 2: Genetic alterations and potentially actionable mutations in pancreatic cancer
Track 3: Targeting BRCA mutations in pancreatic cancer; incidence of microsatellite instability-high disease
Track 4: Current recommendations for genetic testing for patients with pancreatic cancer
Track 5: Molecular profiling for patients with pancreatic cancer: The Know Your Tumor® initiative
Track 6: Ongoing trials investigating targeted therapies for pancreatic cancer
Track 7: Case: A woman in her early 60s with metastatic pancreatic cancer (mPC) and a germline BRCA2 mutation is enrolled on a clinical trial of veliparib with FOLFOX as first-line therapy
Track 8: Activity, safety and ongoing evaluation of PARP inhibitors in combination with chemotherapy for mPC
Track 9: Case: A woman in her early 60s with mPC and a somatic BRCA2 mutation receives FOLFIRINOX followed by maintenance rucaparib on a clinical trial
Track 10: POLO: Design and results of a Phase III trial of olaparib as maintenance therapy for patients with mPC and a germline BRCA mutation after first-line chemotherapy
Track 11: Tolerability of maintenance olaparib on the POLO trial
Track 12: Clinical implications of the POLO trial results
Track 13: Case: A woman in her late 50s with locally advanced pancreatic cancer and a germline ATM mutation is enrolled on a clinical trial of irinotecan, a PARP inhibitor and an ATR inhibitor
Track 14: Response to FOLFOX in patients with locally advanced pancreatic cancer and ATM mutations
Track 15: Case: A man in his early 60s with mPC with a ROS1 fusion receives entrectinib on a clinical trial
Track 16: Clinical experience and dosing considerations with FOLFIRINOX or gemcitabine/nab paclitaxel
Track 17: Use of nal-IRI (nanoliposomal irinotecan) with 5-FU/leucovorin for mPC
Track 18: Importance of supportive and palliative care for patients with mPC
Track 19: Perspective on the use of medical marijuana for patients with mPC
Track 20: Choice of gemcitabine/nab paclitaxel or FOLFIRINOX as first-line therapy for mPC
Track 21: Selection of adjuvant therapy for patients with pancreatic cancer
Track 22: Case: A woman in her mid-50s with localized pancreatic cancer receives neoadjuvant FOLFIRINOX
Track 23: Potential role of PARP inhibitors for pancreatic cancer in the adjuvant setting

Interview with Talia Golan, MD

Track 1: Case: A man in his mid-40s with borderline-resectable adenocarcinoma of the pancreas (PAD) receives neoadjuvant FOLFIRINOX
Track 2: Indications for adjuvant therapy in patients with borderline-resectable PAD
Track 3: Management of borderline-resectable PAD
Track 4: Selection of neoadjuvant therapy for patients with pancreatic cancer
Track 5: Incidence of BRCA mutations in Israel and the United States
Track 6: Case: A woman in her late 70s with node-positive, resectable PAD and multiple comorbidities receives adjuvant gemcitabine/capecitabine
Track 7: Dosing and tolerability of gemcitabine/capecitabine as adjuvant therapy for elderly patients
Track 8: Perspective on the role of surgical resection for older patients with pancreatic cancer
Track 9: Results of the Phase III APACT trial of adjuvant gemcitabine/nab paclitaxel versus gemcitabine alone for surgically resected PAD
Track 10: Choice of FOLFIRINOX versus gemcitabine/nab paclitaxel as first-line therapy for mPC
Track 11: Reduction in the risk of recurrence with adjuvant therapy
Track 12: Perspective on palliative and supportive care for patients with mPC
Track 13: Importance of maintaining quality of life and managing depression for patients with pancreatic cancer
Track 14: Role of medical marijuana in managing symptoms and treatment side effects in pancreatic cancer
Track 15: Single-shot celiac plexus radiosurgery in pancreatic cancer: Palliation and functional outcomes
Track 16: Molecular profiling for patients with pancreatic cancer; spectrum of mutations in DNA damage repair genes
Track 17: Design, eligibility and endpoints of the Phase III POLO trial evaluating olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with mPC and a germline BRCA mutation
Track 18: POLO trial results and clinical experience with olaparib as maintenance therapy
Track 19: Selection and sequencing of therapy for patients with BRCA mutations
Track 20: Side effects associated with PARP inhibitors in patients with pancreatic cancer
Track 21: Response to first-line FOLFIRINOX followed by maintenance olaparib
Track 22: Novel approaches in the management of pancreatic cancer
 
FACULTY
 
Michael J Pishvaian, MD, PhD
Associate Professor
Department of Gastrointestinal Medical Oncology
Co-Director for Clinical Research
Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research
The University of Texas
MD Anderson Cancer Center
Houston, Texas
 
Talia Golan, MD
Medical Director
Phase I Program and Sheba Pancreatic Cancer Program
Sheba Medical Center
Ramat Gan, Israel
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida